Transaction Estimated at Around 600 Billion Won

Daewoong Group announced on March 6 that it has selected IMM PE as the preferred bidder to acquire CG Bio, its affiliate in the regenerative medicine sector.


Exterior view of CGBio Novofactory and S-Campus. Photo by CGBio

Exterior view of CGBio Novofactory and S-Campus. Photo by CGBio

View original image

The stake up for sale is 51% of CG Bio, held by Aihana, a family company owned by the Daewoong Group owner's family and the largest shareholder of CG Bio.


The sale price and acquisition process will be finalized following due diligence and the signing of the main contract. Considering that the market values CG Bio at around 1 trillion won, there are projections that the deal could be made for approximately 600 billion won.



CG Bio manufactures medical devices and therapeutics necessary for the regeneration of human tissues such as bone, skin, and blood vessels. The company posted sales of 200.8 billion won in 2024.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing